Tolerance, not immunity, crucially depends on IL-2

Nature Reviews Immunology

Volumn 4, Issue 9, 2004, Pages 665-674

  Malek, Thomas R ^a   Bayer, Allison L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CYTOKINE RECEPTOR; GROWTH FACTOR RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR BETA; JANUS KINASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SOS PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; AUTOIMMUNITY; CANCER PATIENT; CELL DEATH; CELL REGENERATION; CELL SURVIVAL; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; KIDNEY CARCINOMA; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; CELL DIVISION; CELL SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNITY; INTERLEUKIN-2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 4544241811     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1435     Document Type: Review

References (113)

1. Nelson, B. H. & Willerford, D. M. Biology of the interleukin-2 receptor. Adv. Immunol. 70, 1-81 (1998).
2. He, Y.-W. & Malek, T. R. The structure and function of γc-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. Crit. Rev. Immunol. 18, 503-524 (1998).
3. Parrish-Novak, J., Foster, D. C., Holly, R. D. & Clegg, C. H. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J. Leukoc. Biol. 72, 856-863 (2002).
4. Waldmann, T. A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105-110 (2001).
5. Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253-261 (1993).
6. + T cells. Eur. J. Immunol. 25, 3053-3059 (1995).
7. Sadlack, B., Kuhn, R., Schorle, H., Muller, W. & Horak, I. Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4. Eur. J. Immunol. 24, 281-284 (1994). References 5-7 describe the lymphoproliferation and lethal autoimmunity that is associated with IL-2 deficiency and indicate that the main function of IL-2 is to control peripheral T-cell tolerance.
8. Suzuki, H., Duncan, G. S., Takimoto, H. & Mak, T. W. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor β chain. J. Exp. Med. 185, 499-505 (1997).
9. Willerford, D. M. et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
10. Lodolce, J. P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669-676 (1998).
11. Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771-780 (2000).
12. Morgan, D. A., Ruscetti, F. W. & Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193,1007-1008 (1976).
13. Gillis, S. & Smith, K. A. In vitro generation of tumor-specific cytotoxic lymphocytes. Secondary allogeneic mixed tumor lymphocyte culture of normal murine spleen cells. J. Exp. Med. 146, 468-482 (1977).
14. Taniguchi, T. et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302, 305-310 (1983).
15. Shevach, E. M. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18, 423-449 (2000).
16. Sakaguchi, S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455-458 (2000).
17. + regulatory T Cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562 (2004).
18. Reg cells expressing a functional IL-2R and the host producing IL-2.
19. Papiernik, M., de Moraes, M. L., Pontoux, C., Vasseur, F. & Penit, C. Regulatory CD4 T cells: expression of IL-2Rα chain, resistance to clonal deletion and IL-2 dependency. Int. Immunol. 10, 371-378 (1997).
20. + immunoregulatory T cells suppress polydonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287-296 (1998).
21. + T cell numbers. J. Immunol. 169, 4850-4860 (2002).
22. Webb, G. et al. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin. Immunol. Immunopathol. 81, 282-286 (1996).
23. Suzuki, H., Zhou, Y. W., Kato, M., Mak, T. W. & Nakashima, I. Normal regulatory αβ T cells effectively eliminate abnormally actuated T cells lacking the interleukin 2 receptor β in vivo. J. Exp. Med. 190, 1561-1572 (1999).
24. + T cells to nude mice prevented this abnormal proliferation.
25. + regulatory T cell function. J. Exp. Med. 196, 851-857 (2002).
26. Malek, T. R., Porter, B. O., Codias, E. K., Scibelli, P. & Yu, A. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J. Immunol. 164, 2905-2914 (2000).
27. + memory T cells. J. Immunol. 171, 5853-5864 (2003).
28. Snow, J. W. et al. Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J. Immunol. 171, 5042-5050 (2003).
29. + regulatory T cell homeostasis and the maintenance of self-tolerance. J. Immunol. 171, 3435-3441 (2003).
30. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10, 1969-1980 (1998).
31. + T cell suppressor function. Eur. J. Immunol. 34, 366-376 (2004).
32. Tang, T. et al. In vitro expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199, 1455-1465 (2004).
33. + regulatory T Cells. Blood 104, 895-903 (2004).
34. + regulatory T cells. J. Immunol. 172, 5287-5296 (2004).
35. + regulatory T cells. J. Immunol. 171, 5678-5682 (2003).
36. + suppressor T cells in vivo. Nature Immunol. 3, 33-41 (2002).
37. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
38. + regulatory T cells. J. Immunol. 171, 3348-3352 (2003).
39. + T cell suppressor function. J. Immunol. 172, 6519-6523 (2004).
40. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
41. + regulatory T cells. Nature Immunol. 4, 330-336 (2003).
42. + T regulatory cells. Nature Immunol. 4, 337-342 (2003).
43. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303-310 (2000).
44. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
45. Gorelik, L. & Flavell, R. A. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171-181 (2000).
46. + T cells. J. Exp. Med. 183, 2669-2674 (1996).
47. Asano, M., Toda, M., Sakaguchi, N. & Sakaguchi, S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184, 387-396 (1996).
48. Granucci, F. et al. Indudble IL-2 production by dendritic cells revealed by global gene expression analysis. Nature Immunol. 2, 882-888 (2001).
49. Smith, K. A. T-cell growth factor. Immunol. Rev. 51, 337-357 (1980).
50. He, Y.-W., Nakajima, H., Leonard, W. J., Adkins, B. & Malek, T. R. The common γ-chain of cytokine receptors regulates intrathymic T cell development at multiple stages. J. Immunol. 158, 2592-2599 (1997).
51. Depper, J. M., Leonard, W. J., Robb, R. J., Waldmann, T. A. & Greene, W. C. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J. Immunol. 131, 690-696 (1983).
52. Malek, T. R., Onega, G., Jakway, J. P., Chan, C. & Shevach, E. M. The murine IL2 receptor. II. Monoclonal anti-IL2 receptor antibodies as specific inhibitors of T cell function in vitro. J. Immunol. 133, 1976-1982 (1984).
53. Gillis, S., Gillis, A. E. & Henney, C. S. Monoclonal antibody directed against interleukin 2. I. Inhibition of T lymphocyte mitogenesis and the in vitro differentiation of alloreactive cytolytic T cells. J. Exp. Med. 154, 983-988 (1981).
54. Koretzky, G. A., Daniele, R. P., Greene, W. C. & Nowell, P. C. Evidence for an interleukin-independent pathway for human lymphocyte activation. Proc. Natl Acad. Sci. USA 80, 3444-3447 (1983).
55. Schorle, H., Holtschke, T., Hunig, T., Shimpl, A. & Horak, I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352, 621-624 (1991).
56. + T lymphocytes from interleukin 2-deficient mice by costimulatory B7 molecules. Proc. Natl Acad. Sci. USA 93, 2903-2908 (1996).
57. Van Parijs, L. et al. Functional responses and apoptosis of CD25 (IL-2Rα)-deficient T cells expressing a transgenic antigen receptor. J. Immunol. 158, 3738-3745 (1997).
58. Malek, T. R., Yu, A., Scibelli, P., Lichtenheld, M. G., & Codias, E. K. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J. Immunol. 168, 1675-1683 (2001).
59. Appleman, L. J., Berezovskaya, A., Grass, I. & Boussiotis, V. A. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J. Immunol. 164, 144-151 (2000). This paper shows that co-stimulation through CD28 regulates progression through the G1 phase of the cell cycle in an IL-2-independent manner. In the absence of IL-2, some T cells arrest at the G1-S transition, but a considerable number progress through S phase, indicating that CD28 mediates some T-cell proliferation in an IL-2-independent manner.
60. Cao, X. et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 2, 223-238 (1995).
61. H2 differentiation. Proc. Natl Acad. Sci. USA 101, 3880-3885 (2004).
62. Lenardo, M. J. Interleukin-2 programs αβ lymphocytes for apoptosis. Nature 353, 858-861 (1991).
63. Kneitz, B., Herrmann, T., Yonehara, S. & Schimpl, A. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur. J. Immunol. 25, 2572-2577 (1995).
64. Van Parijs, L. & Abbas, A. K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280, 243-248 (1998).
65. Kung, J., Beller, D. & Ju, S. Lymphokine regulation of activation-induced apoptosis in Tcells of IL-2 and IL-2Rβ knockout mice. Cell. Immunol. 185, 158-163 (1998).
66. Zheng, L., Trageser, C. L., Willerford, D. M. & Lenardo, M. J. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J. Immunol. 160, 763-769 (1998).
67. H cells and NK cells showed reduced activity but were still functionally active. This study was the first to question the idea that IL-2 is essential for T-cell immunity in vivo.
68. Steiger, J., Nickerson, P. W., Steurer, W., Moscovitch-Lopatin, M. & Strom, T. B. IL-2 knockout recipient mice reject islet cell allografts. J. Immunol. 155, 489-498 (1995).
69. Bachmann, M. F. et al. Antiviral immune responses in mice deficient for both interleukin-2 and interleukin-4. J. Virol. 69, 4842-4846 (1995).
70. Nishimura, H. et al. Mice lacking interleukin-2 (IL-2)/IL-15 receptor β chain are susceptible to infection with avirulent Salmonella enterica subsp. enterica serovar choleraesuis but mice lacking IL-2 are resistant. Infect. Immun. 69, 1226-1229 (2001).
71. Suzuki, H., Hayakawa, A., Bouchard, D., Nakashima, I. & Mak, T. W. Normal thymic selection, superantigen-induced deletion and Fas-mediated apoptosis of T cells in IL-2 receptor β-chain deficient mice. Int. Immmunol. 9, 1367-1374 (1997).
72. D'Souza, W. N. & Lefrancois, L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J. Immunol. 171, 5727-5735 (2003).
73. Leung, D. T., Morefield, S. & Willerford, D. M. Regulation of lymphoid homeostasis by IL-2 receptor signals in vivo. J. Immunol. 164, 3527-3534 (2000).
74. D'Souza, W. N., Schluns, K. S., Masopust, D. & Lefrancois, L. Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. J. Immunol. 168, 5566-5572 (2002).
75. Reg-cell production, the resulting immune responses cannot be the result of improper activation, a property that is typically associated with IL-2- or IL-2R-deficiency.
76. Kuhn, R., Rajewsky, K. & Muller, W. Generation and analysis of interleukin-4 deficient mice. Science 254, 707-710 (1991).
77. Cousens, L. P., Orange, J. S. & Biron, C. A. Endogenous IL-2 contributes to T cell expansion and IFN-γ production during lymphocytic choriomeningitis virus infection. J. Immunol. 155, 5690-5699 (1995).
78. + T cell interactions in IFN-γ and IL-4 responses to viral infections: requirements for IL-2. J. Immunol. 160, 5007-5017 (1998).
79. Blattman, J. N. et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nature Med. 9, 540-547 (2003).
80. + T cells increases the size of the acute antiviral response and of the resulting memory T cell pool. J. Immunol. 169, 4990-4997 (2002).
81. + T cells rather than promotion of cell death. Proc. Natl Acad. Sci. USA 99, 3001-3006 (2002). References 79-81 report the effect of systemic IL-2 during the clonal expansion, contraction and memory phases of in vivo T-cell responses to viral infection. IL-2 showed its greatest benefit during the contraction phase of the response, in which it increased proliferation and survival of long-lived virus-specific T cells.
82. Li, X. C. et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nature Med. 7, 114-118 (2001).
83. Sepulveda, H., Cerwenka, A., Morgan, T. & Dutton, R. W. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation. J. Immunol. 163, 1133-1142 (1999).
84. Croft, M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 14, 265-273 (2003).
85. Changelian, P. S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878 (2003).
86. + T cell survival but not antigen proliferation. Nature Immunol. 1, 54-58 (2000).
87. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193, 1295-1302 (2001).
88. + T cells with regulatory properties from human blood. J. Exp. Med. 193, 1303-1310 (2001).
89. + T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193, 1285-1294 (2001).
90. + thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur. J. Immunol. 31, 1247-1254 (2001).
91. + T cells: a highly differentiated and apoptosis-prone population. Eur. J. Immunol. 31, 1122-1131 (2001).
92. + T cells isolated from peripheral blood have in vitro properties and suppressor functions similar to their mouse counterparts.
93. Roifman, C. M. Human IL-2 receptor α chain deficiency. Pediatr. Res. 48, 6-11 (2000).
94. Davey, R. T. Jr et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 284, 183-189 (2000).
95. Kovacs, J. A. et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335, 1350-1356 (1996).
96. Atkins, M. B. Interleukin-2: clinical applications. Semin. Oncol. 29, 12-17 (2002).
97. Yang, J. C. et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
98. + memory T cells by opposing cytokines. Science 288, 675-678 (2000).
99. + T cells. Proc. Natl Acad. Sci. USA 99, 8832-8837 (2002).
100. + T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104, 775-780 (2004).
101. + regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J. Immunol. 168, 5979-5983 (2002).
102. Foss, F. M. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann. NY Acad. Sci. 941, 166-176 (2001).
103. Oncuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128-3133 (1999).
104. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823-832 (2001).
105. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218 (1999).
106. Liyanage, U. K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
107. Woo, E. Y. et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272-4276 (2002).
108. Ichihara, F. et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9, 4404-4408 (2003).
109. Wolf, A. M. et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606-612 (2003).
110. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98, 1089-1099 (2003).
111. Church, A. C. Clinical advances in therapies targeting the interleukin-2 receptor. QJM 96, 91-102 (2003).
112. Waldmann, T. A. & O'Shea, J. The use of antibodies against the IL-2 receptor in transplantation. Curr. Opin. Immunol. 10, 507-512 (1998).
113. Shapiro, A. M. et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343, 230-238 (2000).